3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations
Therapeutic monoclonal antibodies (mAbs) are an emerging and very active frontier in clinical oncology, with hundred molecules currently in use or being tested. These treatments have already revolutionized clinical outcomes in both solid and hematological malignancies. However, identifying patients...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/11/3/46 |
| _version_ | 1827664065075347456 |
|---|---|
| author | Virginia Guzzeloni Lorenzo Veschini Federica Pedica Elisabetta Ferrero Marina Ferrarini |
| author_facet | Virginia Guzzeloni Lorenzo Veschini Federica Pedica Elisabetta Ferrero Marina Ferrarini |
| author_sort | Virginia Guzzeloni |
| collection | DOAJ |
| description | Therapeutic monoclonal antibodies (mAbs) are an emerging and very active frontier in clinical oncology, with hundred molecules currently in use or being tested. These treatments have already revolutionized clinical outcomes in both solid and hematological malignancies. However, identifying patients who are most likely to benefit from mAbs treatment is currently challenging and limiting the impact of such therapies. To overcome this issue, and to fulfill the expectations of mAbs therapies, it is urgently required to develop proper culture models capable of faithfully reproducing the interactions between tumor and its surrounding native microenvironment (TME). Three-dimensional (3D) models which allow the assessment of the impact of drugs on tumors within its TME in a patient-specific context are promising avenues to progressively fill the gap between conventional 2D cultures and animal models, substantially contributing to the achievement of personalized medicine. This review aims to give a brief overview of the currently available 3D models, together with their specific exploitation for therapeutic mAbs testing, underlying advantages and current limitations to a broader use in preclinical oncology. |
| first_indexed | 2024-03-10T00:54:02Z |
| format | Article |
| id | doaj.art-9f172a0d46ab48e799176a51377744aa |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-03-10T00:54:02Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-9f172a0d46ab48e799176a51377744aa2023-11-23T14:46:04ZengMDPI AGAntibodies2073-44682022-07-011134610.3390/antib110300463D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and LimitationsVirginia Guzzeloni0Lorenzo Veschini1Federica Pedica2Elisabetta Ferrero3Marina Ferrarini4B-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyAcademic Centre of Reconstructive Science, Faculty of Dentistry Oral & Craniofacial Sciences, King’s College London, Guy’s Hospital, London SE1 9RT, UKPathology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyB-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyB-Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, ItalyTherapeutic monoclonal antibodies (mAbs) are an emerging and very active frontier in clinical oncology, with hundred molecules currently in use or being tested. These treatments have already revolutionized clinical outcomes in both solid and hematological malignancies. However, identifying patients who are most likely to benefit from mAbs treatment is currently challenging and limiting the impact of such therapies. To overcome this issue, and to fulfill the expectations of mAbs therapies, it is urgently required to develop proper culture models capable of faithfully reproducing the interactions between tumor and its surrounding native microenvironment (TME). Three-dimensional (3D) models which allow the assessment of the impact of drugs on tumors within its TME in a patient-specific context are promising avenues to progressively fill the gap between conventional 2D cultures and animal models, substantially contributing to the achievement of personalized medicine. This review aims to give a brief overview of the currently available 3D models, together with their specific exploitation for therapeutic mAbs testing, underlying advantages and current limitations to a broader use in preclinical oncology.https://www.mdpi.com/2073-4468/11/3/46therapeutic monoclonal antibodies3D modelstumor microenvironmentdrug response |
| spellingShingle | Virginia Guzzeloni Lorenzo Veschini Federica Pedica Elisabetta Ferrero Marina Ferrarini 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations Antibodies therapeutic monoclonal antibodies 3D models tumor microenvironment drug response |
| title | 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations |
| title_full | 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations |
| title_fullStr | 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations |
| title_full_unstemmed | 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations |
| title_short | 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations |
| title_sort | 3d models as a tool to assess the anti tumor efficacy of therapeutic antibodies advantages and limitations |
| topic | therapeutic monoclonal antibodies 3D models tumor microenvironment drug response |
| url | https://www.mdpi.com/2073-4468/11/3/46 |
| work_keys_str_mv | AT virginiaguzzeloni 3dmodelsasatooltoassesstheantitumorefficacyoftherapeuticantibodiesadvantagesandlimitations AT lorenzoveschini 3dmodelsasatooltoassesstheantitumorefficacyoftherapeuticantibodiesadvantagesandlimitations AT federicapedica 3dmodelsasatooltoassesstheantitumorefficacyoftherapeuticantibodiesadvantagesandlimitations AT elisabettaferrero 3dmodelsasatooltoassesstheantitumorefficacyoftherapeuticantibodiesadvantagesandlimitations AT marinaferrarini 3dmodelsasatooltoassesstheantitumorefficacyoftherapeuticantibodiesadvantagesandlimitations |